Colorectal cancer and screening programs: not only analytical issues

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Chemistry and Laboratory Medicine

• Publication date

  2014-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1515/cclm-2014-0508PMID 24897408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist.

  2015cited by this paper
• Diagnostic Performance of Guaiac-Based Fecal Occult Blood Test in Routine Screening: State-Wide Analysis from Bavaria, Germany

  2014cited by this paper
• Faecal haemoglobin concentrations vary with sex and age, but data are not transferable across geography for colorectal cancer screening

  2014cited by this paper
• A new sampling device for faecal immunochemical testing: haemoglobin stability is still an open issue

  2014cited by this paper
• Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients

  2014cited by this paper
• Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT)

  2013cited by this paper
• Diagnostic inconsistency of faecal immunochemical tests for haemoglobin in population screening of colorectal cancer

  2013cited by this paper
• European guidelines for quality assurance in colorectal cancer screening and diagnosis. – First Edition Faecal occult blood testing

  2012cited by this paper
• DNA methylation biomarkers and their utility for solid cancer diagnostics

  2012cited by this paper
• Hepatic arterial infusion in colorectal carcinoma: is anatomical targeting still relevant in an era of molecularly targeted therapy?

  2012cited by this paper
• Laboratory medicine and medical oncology: the tale of two Cinderellas

  2012cited by this paper
• Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer

  2012cited by this paper
• Identification of circulating microRNAs as biomarkers in cancers: what have we got?

  2012cited by this paper
• microRNA and the pathogenesis of ovarian cancer – a new horizon for molecular diagnostics and treatment?

  2012cited by this paper
• Recent progress and clinical importance on pharmacogenetics in cancer therapy

  2011cited by this paper
• Closing the brain-to-brain loop in laboratory testing

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Longitudinal Adherence to Fecal Occult Blood Testing Impacts Colorectal Cancer Screening Quality

  2011cited by this paper
• Effect of Verification Bias on the Sensitivity of Fecal Occult Blood Testing: a Meta-Analysis

  2010cited by this paper
• Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers

  2010cited by this paper
• Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.

  2008cited by this paper
• Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps.

  2008cited by this paper
• Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology * †

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• A Quantitative Immunochemical Fecal Occult Blood Test for Colorectal Neoplasia

  2007cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.

  2001cited by this paper
• Randomised study of screening for colorectal cancer with faecal-occult-blood test.

  1996cited by this paper
• Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

  1993cited by this paper
• Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

  1989cited by this paper

• No citing papers are available for this paper.